https://www.roche.com/media/releases/med-cor-2019-04-01
Data from Phase Ib study to be presented at American Association for Cancer Research (AACR) 2019 annual congress 73% overall response rate (ORR) irrespective...
in combinationrocheipatasertibtecentriqchemotherapy